Introduction to CJC-1295 No DAC 2mg (Modified GRF 1-29)

CJC-1295 No DAC, biochemically classified as Modified GRF (1-29) or Tetrasubstituted Growth Hormone-Releasing Hormone (1-29), is a synthetic peptide analogue engineered to serve as a high-resolution molecular probe in endocrinology, metabolic biochemistry, and cellular survival trials. Modeled after the fully functional biolytic core of endogenous growth hormone-releasing hormone ($\text{GHRH}_{1-29}$), CJC-1295 No DAC plays an imperative role in studying the biological regulation of the mammalian growth hormone axis and pituitary somatotroph dynamics.

In native biological systems, endogenous GHRH possesses an exceptionally brief experimental half-life, subject to rapid enzymatic cleaving within minutes of secretion. To circumvent this rapid degradation without utilizing a Drug Affinity Complex (DAC) conjugation that permanently alters native pulsatile rhythms, this tetrasubstituted configuration incorporates four targeted amino acid substitutions. These modifications significantly enhance structural metabolic stability and receptor affinity. At USA PEPTIDE SCIENCES, we distribute this foundational secretagogue matrix as a premium 2mg lyophilized vial, providing molecular biology and neuroendocrine research institutions with an absolute reference standard for tracking receptor-mediated exocytosis loops.

Research Overview: GHRH Receptor Agonism and Downstream Signaling

The primary scientific value of CJC-1295 No DAC 2mg centers on its profound capability to bind to and activate native GHRH receptors on anterior pituitary somatotroph cells. By functioning as a high-affinity ligand, this peptide allows investigators to map complex downstream intracellular cascades in total isolation from structural degradation variables.

Key areas of active scientific investigation utilizing CJC-1295 No DAC 2mg include:

• Adenylate Cyclase and cAMP Signal Transduction: Modeling the structural activation of the GHRH receptor, which is a G-protein coupled receptor. Upon binding, CJC-1295 No DAC stimulates the $\text{G}_s$ alpha subunit, upregulating adenylate cyclase activity and accelerating the intracellular accumulation of cyclic adenosine monophosphate (cAMP). Researchers track this signaling loop to observe the subsequent activation of protein kinase A (PKA).

• Pulsatile Endocrine Release Profiles: Investigating the preservation of native hormonal fluctuations. Because this configuration lacks the Drug Affinity Complex (DAC) that binds to plasma albumin to force continuous secretion, researchers use the 2mg format to evaluate natural, pulsatile surges of endogenous growth hormone, mapping physiological feedback loops and somatostatin-controlled refractory windows.

• Enzymatic Cleavage Resistance: Analyzing the biochemical impact of the four structural substitutions. Studies focus on how replacing native amino acids at positions 2, 8, 15, and 27 protects the peptide chain from rapid degradation by the circulating enzyme dipeptidyl peptidase-4 (DPP-4), tracing the compound’s extended plasma half-life compared to unmodified $\text{GHRH}_{1-29}$.

• Downstream Growth Factor Upregulation: Evaluating secondary systemic signaling parameters resulting from pituitary secretagogue activation. Researchers monitor the transcriptional upregulation of hepatic insulin-like growth factor 1 (IGF-1) and track subsequent cellular adjustments in protein synthesis, cellular differentiation, and systemic tissue remodeling baselines.

Molecular Architecture and Substitutions

To ensure maximum analytical resolution and structural reproducibility, the molecular structure of CJC-1295 No DAC 2mg features four specific modifications along its 29-amino-acid sequence compared to native GRF (1-29):

• D-Alanine substitution at position 2: Engineered to prevent enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4).

• Glutamine substitution at position 8: Introduced to minimize spontaneous chemical deamidation.

• Alanine substitution at position 15: Utilized to enhance metabolic stability and structural integrity.

• Leucine substitution at position 27: Incorporated to prevent oxidation of the amino acid side chains.

Quality Standards & Analytical Testing

At USA PEPTIDE SCIENCES, laboratory data integrity and compound reproducibility are the fundamental core of our manufacturing operations. Every single production lot of CJC-1295 No DAC 2mg undergoes a strict quality control validation protocol to eliminate compounding variables and experimental artifacts. We utilize High-Performance Liquid Chromatography (HPLC) coupled with Mass Spectrometry (MS) to confirm an absolute chemical purity profile of 99% or greater. This rigorous analytical validation verifies the exact amino acid sequence composition, precise molecular weight, and correct spatial conformation while ensuring the total absence of residual synthesis reagents, truncated fragments, heavy metals, or raw contaminants. A batch-specific Certificate of Analysis (COA) accompanies every order to guarantee absolute reproducibility.

Storage and Handling Requirements

To safeguard the delicate peptide bonds and prevent structural degradation of the 2mg lyophilized cake, all vials must be stored long-term in a freezer environment at -20°C. Prior to introducing the compound into your laboratory workflow, reconstitution must be carried out using an appropriate sterile, non-pyrogenic, or bacteriostatic diluent. Once transitioned into a liquid state, the peptide solution becomes highly sensitive to thermal breakdown and mechanical shear stress; reconstituted vials must be maintained under constant refrigeration at 2°C to 8°C. Researchers must dissolve the compound via a slow, gentle swirling motion, avoiding any aggressive mechanical agitation, inversion, or shaking, which can permanently disrupt the delicate synthetic matrix.

Research Use Disclaimer

The compounds distributed by USA PEPTIDE SCIENCES, including CJC-1295 No DAC 2mg (Mod GRF 1-29) research vials, are designated strictly for laboratory research purposes only. Under no circumstances are these products approved or intended for human or veterinary consumption, direct clinical diagnostics, or therapeutic drug administration. All handling, measuring, and experimental evaluation must be conducted exclusively by qualified scientific professionals within a certified and monitored research facility.